<?xml version="1.0" encoding="UTF-8"?>
<document>
<type>mainstream</type>
<forum>http://www.mideasttime.com/feed</forum>
<forum_title>Mideast Time</forum_title>
<discussion_title>Analysts Set Imperva Inc. (NYSE:IMPV) Price Target at $55.90</discussion_title>
<language>english</language>
<gmt_offset></gmt_offset>
<topic_url>http://www.mideasttime.com/analysts-set-imperva-inc-nyseimpv-price-target-at-55-90/1212644/</topic_url>
<topic_text>
Tweet 
Shares of Imperva Inc. (NYSE:IMPV) have been given an average rating of “Buy” by the twenty-five research firms that are currently covering the firm. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and seventeen have issued a buy rating on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $55.90. 
Shares of Imperva ( NYSE:IMPV ) opened at 47.51 on Friday. Imperva has a 1-year low of $31.11 and a 1-year high of $77.99. The firm has a 50-day moving average price of $45.99 and a 200-day moving average price of $43.63. The company’s market capitalization is $1.55 billion. 
Imperva (NYSE:IMPV) last posted its earnings results on Thursday, August 4th. The company reported ($0.23) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.04) by $0.19. The company earned $57.87 million during the quarter, compared to analysts’ expectations of $66.06 million. During the same period in the prior year, the business posted ($0.08) EPS. The business’s revenue was up 8.2% on a year-over-year basis. Equities analysts anticipate that Imperva will post ($0.80) earnings per share for the current year. 
In related news, insider Amichai Shulman sold 3,085 shares of the company’s stock in a transaction dated Wednesday, July 27th. The stock was sold at an average price of $46.28, for a total value of $142,773.80. Following the completion of the sale, the insider now owns 93,380 shares in the company, valued at $4,321,626.40. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at the SEC website . Also, CEO Anthony J. Bettencourt sold 50,000 shares of the company’s stock in a transaction dated Wednesday, May 25th. The shares were sold at an average price of $36.15, for a total value of $1,807,500.00. Following the completion of the sale, the chief executive officer now owns 52,938 shares of the company’s stock, valued at approximately $1,913,708.70. The disclosure for this sale can be found here . 
IMPV has been the topic of several recent analyst reports. Wunderlich dropped their price target on Imperva from $62.00 to $50.00 and set a “buy” rating on the stock in a research report on Friday, May 6th. Needham &amp; Company LLC downgraded Imperva from a “buy” rating to a “hold” rating in a research report on Friday, May 6th. Oppenheimer Holdings Inc. reaffirmed a “buy” rating and issued a $60.00 price target (down from $70.00) on shares of Imperva in a research report on Friday, May 6th. Morgan Stanley reaffirmed a “sell” rating and issued a $34.00 price target on shares of Imperva in a research report on Friday, May 6th. Finally, Royal Bank Of Canada reaffirmed a “buy” rating and issued a $55.00 price target on shares of Imperva in a research report on Thursday, May 12th. 
Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company operates in the segment of development, marketing, sales, service and support of cyber-security solutions that protect business critical data and applications whether in the cloud or on premises.   Imperva Inc.   Imperva Inc.  
</topic_text>
<spam_score>0.00</spam_score>
<post_num>1</post_num>
<post_id>post-1</post_id>
<post_url>http://www.mideasttime.com/analysts-set-imperva-inc-nyseimpv-price-target-at-55-90/1212644/</post_url>
<post_date>20160822</post_date>
<post_time>0751</post_time>
<username>Shayan Afkhami</username>
<post>
Tweet 
Shares of Imperva Inc. (NYSE:IMPV) have been given an average rating of “Buy” by the twenty-five research firms that are currently covering the firm. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and seventeen have issued a buy rating on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $55.90. 
Shares of Imperva ( NYSE:IMPV ) opened at 47.51 on Friday. Imperva has a 1-year low of $31.11 and a 1-year high of $77.99. The firm has a 50-day moving average price of $45.99 and a 200-day moving average price of $43.63. The company’s market capitalization is $1.55 billion. 
Imperva (NYSE:IMPV) last posted its earnings results on Thursday, August 4th. The company reported ($0.23) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.04) by $0.19. The company earned $57.87 million during the quarter, compared to analysts’ expectations of $66.06 million. During the same period in the prior year, the business posted ($0.08) EPS. The business’s revenue was up 8.2% on a year-over-year basis. Equities analysts anticipate that Imperva will post ($0.80) earnings per share for the current year. 
In related news, insider Amichai Shulman sold 3,085 shares of the company’s stock in a transaction dated Wednesday, July 27th. The stock was sold at an average price of $46.28, for a total value of $142,773.80. Following the completion of the sale, the insider now owns 93,380 shares in the company, valued at $4,321,626.40. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at the SEC website . Also, CEO Anthony J. Bettencourt sold 50,000 shares of the company’s stock in a transaction dated Wednesday, May 25th. The shares were sold at an average price of $36.15, for a total value of $1,807,500.00. Following the completion of the sale, the chief executive officer now owns 52,938 shares of the company’s stock, valued at approximately $1,913,708.70. The disclosure for this sale can be found here . 
IMPV has been the topic of several recent analyst reports. Wunderlich dropped their price target on Imperva from $62.00 to $50.00 and set a “buy” rating on the stock in a research report on Friday, May 6th. Needham &amp; Company LLC downgraded Imperva from a “buy” rating to a “hold” rating in a research report on Friday, May 6th. Oppenheimer Holdings Inc. reaffirmed a “buy” rating and issued a $60.00 price target (down from $70.00) on shares of Imperva in a research report on Friday, May 6th. Morgan Stanley reaffirmed a “sell” rating and issued a $34.00 price target on shares of Imperva in a research report on Friday, May 6th. Finally, Royal Bank Of Canada reaffirmed a “buy” rating and issued a $55.00 price target on shares of Imperva in a research report on Thursday, May 12th. 
Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company operates in the segment of development, marketing, sales, service and support of cyber-security solutions that protect business critical data and applications whether in the cloud or on premises.   Imperva Inc.   Imperva Inc.  
</post>
<signature>

</signature>
<external_links>

</external_links>
<country>EU</country>
<main_image>http://www.mideasttime.com/logos/imperva-logo.jpg</main_image>
</document>
